FAQs

Traditional immunosuppressive therapies broadly dampen immune activity and can increase susceptibility to infection. Antigen-specific immune tolerance therapies are designed to selectively target the immune response driving disease while leaving protective immunity intact. This specificity is what makes the approach particularly attractive as a precision immunology strategy. 

The aim of antigen-specific immune tolerance is to address the underlying immune dysfunction rather than simply manage symptoms. By re-establishing tolerance to disease-driving antigens, developers hope to achieve long-lasting remission. Whether this can be consistently achieved remains one of the central questions facing the field. 

Key challenges include identifying the right antigens, translating promising preclinical findings into clinical success, establishing reliable biomarkers of tolerance and demonstrating durable efficacy. Disease heterogeneity, patient selection, and the lack of validated immune monitoring endpoints continue to complicate development across multiple indications. 

Biomarkers of tolerance are measurable indicators that a therapy is successfully reprogramming the immune system. They may include changes in T-cell populations, TCR repertoire, cytokine profiles, autoantibodies, or regulatory T-cell activity. Robust biomarkers are critical for patient stratification, clinical development, regulatory discussions, and demonstrating that immune modulation is translating into meaningful biological effects. 

Durability refers to how long therapeutic benefit persists after treatment. Developers assess durability through long-term clinical outcomes, biomarker stability, relapse rates, and evidence that immune regulation is maintained without ongoing intervention. Demonstrating durable responses is increasingly viewed as one of the strongest indicators that true tolerance has been achieved. 

Antigen selection is fundamental to the success of any antigen-specific therapy. Developers must identify antigens that are genuinely involved in disease pathology while accounting for patient heterogeneity and antigen spreading. Advances in antigen discovery, epitope mapping, and immune profiling are helping researchers refine target selection and improve the likelihood of clinical success. 

The most advanced programs are focused on type 1 diabetes, celiac disease, and multiple sclerosis, although research is expanding into rheumatoid arthritis, inflammatory bowel disease, and other immune-mediated disorders. Progress in these indications is helping establish the clinical, biomarker, and regulatory frameworks that may support broader adoption of antigen-specific therapies across autoimmune diseases.